PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models

BACKGROUND: PG545 is a heparan sulfate (HS) mimetic that inhibits tumour angiogenesis by sequestering angiogenic growth factors in the extracellular matrix (ECM), thus limiting subsequent binding to receptors. Importantly, PG545 also inhibits heparanase, the only endoglycosidase which cleaves HS cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Dredge, K, Hammond, E, Handley, P, Gonda, T J, Smith, M T, Vincent, C, Brandt, R, Ferro, V, Bytheway, I
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049593/
https://www.ncbi.nlm.nih.gov/pubmed/21285983
http://dx.doi.org/10.1038/bjc.2011.11

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049593/
https://www.ncbi.nlm.nih.gov/pubmed/21285983
http://dx.doi.org/10.1038/bjc.2011.11

Ejemplares similares